Connect with us


How To Participate in Psychedelic Clinical Trials

First and foremost, if you’re located in South Florida, head over to our affiliate website to apply for active clinical studies. Or, you can fill out…



First and foremost, if you’re located in South Florida, head over to our affiliate website to apply for active clinical studies. Or, you can fill out the contact form below.

Participate in a South Florida Study

Psychedelic substances, long stigmatized and relegated to the fringes of medical research, are now emerging as potential game-changers in the treatment of various mental health conditions. From PTSD and depression to anxiety and addiction, these substances are being rigorously tested for their therapeutic potential. If you are considering participating in one of these groundbreaking studies, understanding the enrollment process is crucial. This article provides a comprehensive guide on how to enroll in psychedelic clinical trials, focusing on the studies available through Segal Trials and the Clexio Biosciences study detailed in the attached document.

Understanding Psychedelic Clinical Trials

The Promise of Psychedelics in Mental Health Treatment

Psychedelics, such as psilocybin, MDMA, and LSD, have shown promise in treating conditions that are resistant to traditional therapies. These substances can profoundly impact brain function and emotional regulation, offering new hope for patients with chronic mental health issues. Clinical trials are essential in scientifically validating the safety and efficacy of these treatments.

Eligibility for Psychedelic Clinical Trials

General Inclusion and Exclusion Criteria

To participate in a psychedelic clinical trial, you must meet specific inclusion and exclusion criteria. These criteria ensure the safety of participants and the integrity of the study. Common inclusion criteria include:

  • Age requirements (usually between 18-65 years)
  • Specific mental health diagnoses (e.g., PTSD, MDD)
  • Failure to respond to conventional treatments

Exclusion criteria often involve:

  • History of certain medical conditions (e.g., bipolar disorder, schizophrenia)
  • Current substance abuse
  • Pregnancy or breastfeeding

Enrolling in Segal Trials’ Psychedelic Studies

Study 1: Psilocybin-Assisted Therapy for Major Depressive Disorder

One of the prominent studies at Segal Trials focuses on psilocybin-assisted therapy for Major Depressive Disorder (MDD). This study aims to evaluate the efficacy of psilocybin, a naturally occurring psychedelic compound, in treating depression that has not responded to standard treatments.

Key Eligibility Criteria

  • Age: 18-65 years
  • Diagnosis: Major Depressive Disorder, single or recurrent episodes
  • Treatment History: Inadequate response to at least two antidepressant medications
  • Health: No history of bipolar disorder, schizophrenia, or other psychotic disorders

Study Process

Participants will undergo a comprehensive screening process, including psychological evaluations and medical examinations. The study involves several visits, during which participants receive psilocybin or a placebo under the supervision of trained professionals. Continuous monitoring ensures the safety and well-being of participants.

Study 2: MDMA-Assisted Therapy for PTSD

Another critical study at Segal Trials explores the use of MDMA-assisted therapy for patients with PTSD. This study aims to assess the potential of MDMA, a psychoactive drug, in alleviating the symptoms of PTSD.

Key Eligibility Criteria

  • Age: 18-65 years
  • Diagnosis: Post-Traumatic Stress Disorder (PTSD)
  • Treatment History: Failure to improve with conventional treatments
  • Health: No severe cardiovascular issues, substance abuse, or psychotic disorders

Study Process

Participants in the MDMA-assisted therapy study will also undergo thorough screening. The treatment phase includes MDMA administration in a controlled setting, followed by therapy sessions to help process the experiences and integrate them into everyday life.

CLE100-MDD-202 Study by Clexio Biosciences

A Closer Look at the CLE100-MDD-202 Study

The CLE100-MDD-202 study, conducted by Clexio Biosciences, focuses on assessing the efficacy and safety of CLE-100 as an adjunctive treatment for patients with Major Depressive Disorder who have not adequately responded to standard antidepressants.

Key Eligibility Criteria

  • Age: 18-65 years
  • Diagnosis: Major Depressive Disorder, single or recurrent episodes
  • Treatment History: Inadequate response to at least two antidepressants
  • Health: No history of bipolar disorder, schizophrenia, or other psychotic disorders

Study Design and Duration

The study consists of several phases:

  • Screening Period: Up to 28 days
  • Double-Blind Treatment Period: 29 days
  • Open-Label Extension Period: 24 weeks
  • Follow-Up: Safety follow-up visits after the treatment period

Participants receive either the CLE-100 or a placebo in addition to their current antidepressant medication. The open-label extension allows all participants to receive the study drug after the initial treatment period.

Steps to Enroll in Psychedelic Clinical Trials

Initial Contact and Pre-Screening

The first step in enrolling in a psychedelic clinical trial is to contact the study coordinators. This initial contact often involves a pre-screening questionnaire to determine basic eligibility. For the studies at Segal Trials, you can visit their website and fill out the pre-screening forms online.

Comprehensive Screening Process

If you pass the pre-screening, you will be invited for a comprehensive screening process. This involves detailed medical and psychological evaluations to ensure you meet the specific criteria for the study. It is crucial to provide accurate medical history and current medication details during this phase.

Informed Consent

Before participating, you will need to provide informed consent. This process ensures you understand the study’s purpose, procedures, potential risks, and benefits. It is an opportunity to ask any questions you may have about the trial.

Baseline Assessments

Once enrolled, baseline assessments are conducted to establish your starting point for the study. These assessments typically include psychological tests, physical exams, and laboratory tests.

Treatment Phase

During the treatment phase, you will receive the psychedelic substance (or placebo) under controlled conditions. This phase often includes multiple visits to the study site, where you will be monitored by healthcare professionals.

Follow-Up and Monitoring

After the treatment phase, follow-up visits are crucial to monitor your progress and any long-term effects of the treatment. These visits help researchers gather valuable data on the efficacy and safety of the psychedelic therapy.

Benefits of Participating in Psychedelic Clinical Trials

Access to Cutting-Edge Treatments

Participating in a clinical trial gives you access to innovative treatments that are not yet available to the general public. These treatments may offer significant improvements in your mental health condition, especially if you have not responded to traditional therapies.

Contributing to Scientific Knowledge

By participating in a clinical trial, you contribute to the advancement of medical science. Your involvement helps researchers gather critical data that can lead to new, effective treatments for mental health disorders.

Comprehensive Care and Monitoring

Clinical trial participants receive thorough medical care and monitoring throughout the study. This ensures any adverse effects are promptly addressed and provides an added layer of support for your mental health journey.

Challenges and Considerations

Potential Risks and Side Effects

While clinical trials are designed to ensure participant safety, there are always potential risks and side effects associated with experimental treatments. It is essential to discuss these risks with the study coordinators and weigh them against the potential benefits.

Time Commitment

Participating in a clinical trial requires a significant time commitment, including multiple visits to the study site and follow-up appointments. Ensure you can accommodate this commitment before enrolling.

Emotional and Psychological Impact

The experience of taking a psychedelic substance can be intense and may have a profound emotional and psychological impact. It is crucial to have a robust support system and access to mental health professionals throughout the trial.

Frequently Asked Questions

What are psychedelic clinical trials?

Psychedelic clinical trials are research studies that evaluate the safety and efficacy of psychedelic substances, such as psilocybin and MDMA, in treating mental health conditions.

How can I find psychedelic clinical trials near me?

You can find psychedelic clinical trials through clinical trial registries, research institutions, and organizations like Segal Trials. Websites like also list ongoing studies.

What should I expect during the screening process?

The screening process involves medical and psychological evaluations to determine if you meet the eligibility criteria for the study. This includes interviews, physical exams, and laboratory tests.

Are there any costs associated with participating in a clinical trial?

Most clinical trials cover the cost of treatment and associated medical care. Participants may also receive compensation for their time and travel expenses.

What happens if I experience side effects during the trial?

If you experience side effects, you should report them to the study coordinators immediately. Clinical trials have protocols in place to address adverse effects and ensure participant safety.

Can I withdraw from a clinical trial at any time?

Yes, participation in a clinical trial is voluntary, and you can withdraw at any time. It is essential to communicate your decision to the study coordinators and follow the proper procedures for withdrawal.


Enrolling in psychedelic clinical trials offers a unique opportunity to contribute to groundbreaking research while potentially accessing new and effective treatments for mental health conditions. By understanding the enrollment process, eligibility criteria, and the benefits and challenges involved, you can make an informed decision about participating in these studies. Whether you choose to join the psilocybin and MDMA trials at Segal Trials or the CLE100-MDD-202 study by Clexio Biosciences, your participation is a vital part of advancing the field of psychedelic therapy.

Please fill out the form below if you’re interested in an active psychedelic clinical trial.

Participate in a South Florida Study

Read More